NKTR

NEKTAR THERAPEUTICS

NKTR · CIK 906709 · Annual (10-K) · Last 8 years

Financial Trends

Revenue$98M
20172024
Net Income−$119M
20172024
Operating CF−$176M
20172024
Free Cash Flow−$177M
20172024

Income Statement

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕FY 2017↕
Revenue$0.1B$0.1B$0.1B$0.0B$0.0B$0.0B$0.0B$0.1B
Cost of Revenue$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B—
Gross Profit————————
R&D Expense$0.1B$0.1B$0.2B$0.1B$0.1B$0.1B$0.1B$0.1B
SG&A Expense————————
Operating Income$-0.1B$-0.3B$-0.4B$-0.1B$-0.1B$-0.1B$-0.1B$-0.0B
Net Income$-0.1B$-0.3B$-0.4B$-0.1B$-0.1B$-0.1B$-0.1B$-0.0B
EPS (Basic)$-0.58$-1.45$-1.97$-790.00$-0.65$-0.64$-0.57$-0.21
EPS (Diluted)$-0.58$-1.45$-1.97$-790.00$-0.65$-0.64$-0.57$-0.21

Balance Sheet

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕FY 2017↕
Total Assets$0.3B$0.4B$0.7B$1.1B$1.5B$2.0B$2.2B$0.5B
Current Assets$0.3B$0.3B$0.5B$0.8B$1.1B$1.4B$1.4B$0.3B
Cash & Equivalents$0.0B$0.0B$0.1B$0.0B$0.2B$0.1B$0.2B$0.0B
Total Liabilities$0.2B$0.3B$0.3B$0.4B$0.5B$0.6B$0.4B$0.4B
Current Liabilities$0.1B$0.1B$0.1B$0.1B$0.1B$0.4B$0.1B$0.1B
Stockholders' Equity$0.1B$0.1B$0.4B$0.7B$1.1B$1.4B$1.7B$0.1B

Cash Flow Statement

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕FY 2017↕
Operating Cash Flow$-0.2B$-0.2B$-0.3B$-0.4B$-0.3B$-0.3B$0.7B—
Investing Cash Flow$0.1B$0.1B$0.4B$0.2B$0.5B$0.2B$-1.4B—
Capital Expenditures$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Financing Cash Flow$0.0B$0.0B$0.0B$0.0B$-0.1B$0.0B$0.9B—
← Companies